Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region
Brian Johnston, Paul Thuras, Stephen B. Porter, Melissa Anacker, Brittany VonBank, Paula Snippes Vagnone, Medora Witwer, Mariana Castanheira, James R. Johnson
Abstract
Emerging carbapenem resistance in Escherichia coli , including sequence type 131 (ST131), the leading cause of extraintestinal E. coli infections globally, threatens therapeutic efficacy. Accordingly, we determined broth microdilution MICs for three distinctive newer agents, i.e., cefiderocol (CFDC), ceftazidime-avibactam (CZA), and eravacycline (ERV), plus 11 comparators, against 343 carbapenem-resistant (CR) clinical E. coli isolates, then compared susceptibility results with bacterial characteristics and region.
Topics & Concepts
Ceftazidime/avibactamBiologyMicrobiologyAvibactamBroth microdilutionKlebsiella pneumoniaeCeftazidimeTigecyclineEscherichia coliEnterobacteriaceaeBacteriaAntibioticsGenePseudomonas aeruginosaGeneticsMinimum inhibitory concentrationAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPharmaceutical and Antibiotic Environmental Impacts